Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Blood Advances|March 8, 2021
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severityJohan Courjon, Océane Dufies, Alexandre Robert, et al.
International Journal of Antimicrobial Agents|August 11, 2019
French national cohort of first use of dalbavancin: A high proportion of off-label useAurélien Dinh, Clara Duran, Patricia Pavese, et al.
JAMA Dermatology|November 25, 2020
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 PandemicThomas Hubiche, Nathalie Cardot-Leccia, Florence Le Duff, et al.
The Journal of Experimental Medicine|August 30, 2024
RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activationAnne Doye, Paul Chaintreuil, Chantal Lagresle-Peyrou, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
Real-Life Cefiderocol Use in Bone and Joint Infection: A French National CohortAva Diarra, Maxime Degrendel, Isabelle Eberl, et al.
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
Scientific Reports|April 24, 2025
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trialDavid M Smadja, Clément R Massonnaud, Aurélien Philippe, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Pageof 5